HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jung Won Shin

Jung Won is a reporter based in Seoul covering South Korea, most recently working for PharmAsia News. Her work covers corporate activities in the South Korean pharma/biotech sector as well as government policy and regulatory news. In her role, Jung Won focuses on R&D strategies, clinical development, licensing deals and other major corporate deals and activities in the country's pharma/biotech sector as well as major government measures or regulatory activities in the sector. 
Prior to joining Informa, Jung Won worked for Dow Jones Newswires in Seoul, covering stories in various industries and government. Outside of work, she likes to travel and spend time with her family and friends.

Latest From Jung Won Shin

Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights

Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio

Deals M & A

AriBio Progresses Novel Alzheimer's Contender Despite Mixed Phase II

Korea's AriBio is poised to file for US Phase III trial approval this year for its novel Alzheimer's candidate and lead asset AR1001, which showed an improvement in cognitive function from baseline at Phase II. But will the benefits over existing therapies be enough to carve a position in the challenging field?

Neurology Clinical Trials

Yposkesi Acquisition Fuels SK's Global Push Into Biologics Manufacturing

South Korean conglomerate SK Group continues its cross-border acquisitions of contract manufacturers, this time of French biologics specialist Yposkesi, marking a new push into the gene and cell therapy sector as it looks to become a global leader in the production of both innovative chemical drugs and biologics.

Deals Manufacturing

Samsung Bioepis On The Secrets Of Its Success

Since being established in 2012, Samsung Bioepis has grown into a global biosimilars leader with one of the most robust portfolios of products and pipelines in the sector. Its executive vice-president talks about what is behind this rapid growth and the strategy the Samsung Group affiliate is pursuing to cope with the COVID-19 pandemic and become a fully integrated operation in the longer term.

Biosimilars Strategy

Samsung Bioepis On The Secrets Of Its Success

Since being established in 2012, Samsung Bioepis has grown into a global biosimilars leader with one of the most robust portfolios of products and pipelines in the sector. Its executive vice-president tells Scrip what’s behind this rapid growth and the strategy the Samsung Group affiliate is pursuing to cope with the COVID-19 pandemic and become a fully integrated operation in the longer term.

Biosimilars Business Strategies

Standigm Races AI Rivals To Become Global Discovery Contender

The South Korean AI-driven drug discovery venture is vying with global rivals in the space to show concrete validation of its approaches in partnered projects, while eyeing international expansion and new fundraising, its CEO says.

South Korea Artificial Intelligence
See All
UsernamePublicRestriction

Register